Although the HMGB2-positive rate in CD3-CD16+ NK cells showed an upward trend in ESCC patients (55.69 ± 2.99%), the difference compared to healthy controls was not statistically significant (p = 0.088) (Figures 3a, b). The gene discussed is HMGB2; the disease is esophageal squamous cell carcinoma.